Publication | Closed Access

Cost Effectiveness of Alectinib vs. Crizotinib in First-Line Anaplastic Lymphoma Kinase-Positive Advanced Non-Small-Cell Lung Cancer

OncologyCancer ManagementPathologyBronchial NeoplasmImmune Checkpoint InhibitorCost EffectivenessCancer TreatmentMedicineLung Cancer